Literature DB >> 21537921

Tolvaptan for heart failure patients with volume overload.

Masatsugu Hori1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21537921     DOI： 10.1007/s10557-011-6298-4

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


× No keyword cloud information.
  3 in total

1.  Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.

Authors:  Hiroyuki Nakanishi; Masayuki Kurosaki; Takanori Hosokawa; Yuka Takahashi; Jun Itakura; Shoko Suzuki; Yutaka Yasui; Nobuharu Tamaki; Natsuko Nakakuki; Hitomi Takada; Mayu Higuchi; Yasuyuki Komiyama; Tsubasa Yoshida; Kenta Takaura; Tsuguru Hayashi; Konomi Kuwabara; Sei Sasaki; Namiki Izumi
Journal:  J Gastroenterol       Date:  2015-11-26       Impact factor: 7.527

2.  Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan.

Authors:  Isao Sakaida; Koji Nakajima; Kiwamu Okita; Masatsugu Hori; Tohru Izumi; Masaya Sakurai; Yoshiyuki Shibasaki; Sayaka Tachikawa; Hidetsugu Tsubouchi; Hiromi Oka; Hiroyuki Kobayashi
Journal:  J Gastroenterol       Date:  2015-02-18       Impact factor: 7.527

3.  Triple Diuretics and Aquaretic Strategy for Acute Decompensated Heart Failure due to Volume Overload.

Authors:  Rita Jermyn; Naveed Rajper; Chelsea Estrada; Sagar Patel; Michelle Weisfelner Bloom; Nand K Wadhwa
Journal:  Case Rep Cardiol       Date:  2013-12-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.